Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11008861 | 0.84 | MRGPRX4 (0.51) | MRGPRX4 | |
| SCHEMBL9501757 | 0.82 | MAPK1 (0.41) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL12412421 | 0.80 | CYP2C19 (0.64) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL2641277 | 0.78 | TDP1 (0.56) | SMN1; SMN2GAAMAPTNPSR1MRGPRX4 | |
| SCHEMBL4642505 | 0.76 | CYP2C19 (1.00) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL15187971 | 0.75 | SMN1; SMN2 (0.59) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL14099121 | 0.75 | CYP2C19 (0.59) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL11340763 | 0.75 | CYP2C19 (0.63) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL799545 | 0.73 | CYP2C19 (0.56) | CYP2C19KDM4ESMN1; SMN2GAARXRA | |
| SCHEMBL19728976 | 0.73 | RXRA (0.71) | CYP2C19KDM4ESMN1; SMN2GAARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | claimed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | disclosed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | PNP, NUDT1, ADAR | CYP2C19 3594/4885KDM4E 2725/4885SMN1; SMN2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.